We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+60.37%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.46B
AUM Growth
+$766M
Cap. Flow
-$128M
Cap. Flow %
-3.7%
Top 10 Hldgs %
44.87%
Holding
104
New
18
Increased
30
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$55.7M
2
CELC icon
Celcuity
CELC
+$53M
3
ROIV icon
Roivant Sciences
ROIV
+$50M
4
PEN icon
Penumbra
PEN
+$47.4M
5
MRUS
Merus
MRUS
+$42M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$520M
2
SLNO
Soleno Therapeutics
SLNO
+$36.1M
3
AORT icon
Artivion
AORT
+$29.2M
4
BBNX
Beta Bionics
BBNX
+$23.1M
5
EOLS icon
Evolus
EOLS
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
DELISTED
Astria Therapeutics
ATXS
$47.2M 1.36%
6,485,420
– –
INBX icon
27
Inhibrx
INBX
$1.28B
$44.7M 1.29%
1,327,707
+349,815
+36% +$8.61M
RGEN icon
28
Repligen
RGEN
$8.31B
$36.1M 1.04%
270,428
+104,428
+63% +$12.7M
ZYME icon
29
Zymeworks
ZYME
$1.78B
$35.7M 1.03%
2,090,663
+815,389
+64% +$11.7M
SION
30
Sionna Therapeutics
SION
$2.23B
$34.7M 1%
1,179,098
-36,947
-3% -$804K
CAI
31
Caris Life Sciences
CAI
$4.66B
$33.2M 0.96%
1,098,163
– –
ABVX
32
Abivax
ABVX
$11.9B
$33M 0.95%
+388,608
New +$23.8M
VRDN icon
33
Viridian Therapeutics
VRDN
$1.99B
$31.6M 0.91%
1,462,400
+1,014,893
+227% +$18.3M
CTMX icon
34
CytomX Therapeutics
CTMX
$788M
$30.9M 0.89%
9,680,185
+2,686,539
+38% +$6.05M
BSX icon
35
Boston Scientific
BSX
$65.4B
$30.3M 0.87%
310,000
+30,000
+11% +$3.11M
ALDX icon
36
Aldeyra Therapeutics
ALDX
$102M
$27.3M 0.79%
5,222,311
+1,170,680
+29% +$6.1M
DRUG
37
Bright Minds Biosciences
DRUG
$747M
$27.3M 0.79%
449,290
+28,600
+7% +$1.11M
IMVT icon
38
Immunovant
IMVT
$8.27B
$25.6M 0.74%
1,587,890
-550,000
-26% -$8.9M
EXAS
39
DELISTED
Exact Sciences
EXAS
$25.5M 0.74%
+465,487
New +$23.3M
PVLA
40
Palvella Therapeutics
PVLA
$2.26B
$24.8M 0.72%
+395,093
New +$17.6M
ORKA
41
Oruka Therapeutics
ORKA
$5.59B
$24.4M 0.7%
+1,268,021
New +$18.8M
ISRG icon
42
Intuitive Surgical
ISRG
$122B
$23.3M 0.67%
52,119
+7,000
+16% +$3.36M
IRTC icon
43
iRhythm Holdings
IRTC
$3.64B
$21.2M 0.61%
+123,000
New +$19.6M
AQST icon
44
Aquestive Therapeutics
AQST
$517M
$21M 0.61%
3,760,099
+1,569,679
+72% +$6.79M
SYRE icon
45
Spyre Therapeutics
SYRE
$8.7B
$20.6M 0.6%
1,229,445
-300,000
-20% -$4.89M
ADGM
46
Adagio Medical Holdings
ADGM
$11.8M
$19.2M 0.55%
9,876,576
– –
AXSM icon
47
Axsome Therapeutics
AXSM
$11.8B
$18.1M 0.52%
148,900
-49,634
-25% -$5.59M
ADMA icon
48
ADMA Biologics
ADMA
$2.02B
$16.9M 0.49%
1,153,468
-150,000
-12% -$2.57M
ENGN icon
49
enGene Therapeutics
ENGN
$122M
$14.3M 0.41%
+2,097,236
New +$9.56M
OBIO icon
50
Orchestra BioMed
OBIO
$220M
$13.1M 0.38%
5,292,556
+700,000
+15% +$1.93M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Perceptive Advisors held 104 positions worth $3.46B, up 28% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $128M in Q3 2025, closing 12 positions and reducing 19 holdings. Its most notable exit was Soleno Therapeutics, an estimated $36.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Abivax worth $33M.

  • Perceptive Advisors's largest Q3 2025 buy was Abivax: 388,608 shares worth $33M.
  • Perceptive Advisors added most to Travere Therapeutics in Q3 2025, an estimated $55.7M increase.
  • Perceptive Advisors's biggest Q3 2025 reduction was Verona Pharma, cutting an estimated $520M.
  • Perceptive Advisors fully exited Soleno Therapeutics in Q3 2025, selling an estimated $36.1M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $3.46B portfolio in Q3 2025.
  • Perceptive Advisors opened 18 new positions and closed 12 in Q3 2025.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $3.46B.

Based on Perceptive Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.